Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3552W HIGH $4.60
Volume
817.92 K
Value Traded
3.85 M
Short % Float
10.27%
-0.8%Week
-10.79%1 Month
-35.75%3 Month
-22.98%6 Month
-59.39%5 Year
-99.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
201.53 M
EPS (TTM)
-1.21
P/E Ratio
-
Ent. Value
112.77 M
Total Shares
81.26 M
Float Shares
80.43 M
Insiders
1.02%
Institutions
62.52%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ELDN Catalyst Timeline
Dated clinical, regulatory and corporate events for Eledon Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eledon Pharmaceuticals, Inc.
383Total events
8Upcoming
75Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Long Term DataTegoprubartClinical Data
Updated long-term Phase 2 BESTOW extension results presented at TTS Congress
kidney transplantsource ↗
●IND SubmissionTegoprubartIND
IND submitted to FDA for Eledon-sponsored islet cell transplantation study in type 1 diabetes
type 1 diabetessource ↗
▲Enrollment MilestoneTegoprubartTrial
First patients enrolled in investigator-initiated study in islet cell transplant recipients with T1D and renal dysfunction
type 1 diabetes and chronic kidney diseasesource ↗
▲First Patient DosedTegoprubartTrial
First islet cell transplant recipient dosed with tegoprubart under compassionate use following conversion from tacrolimus
islet cell transplantationsource ↗
▲Enrollment UpdateTegoprubartTrial
UChicago Medicine investigator-initiated islet cell transplantation study expanded by three patients
type 1 diabetes undergoing islet cell transplantationsource ↗
▲End Of Phase 2 MeetingTegoprubartFDA Meeting
Successful End-of-Phase 2 meeting with FDA for tegoprubart in kidney transplantation
kidney transplantationsource ↗
▲First Patient DosedTegoprubartTrial
Treated the first two patients in investigator-initiated study of kidney transplant tolerance induction at Massachusetts General Hospital
kidney transplant tolerance inductionsource ↗
▲Partnership / LicenseTegoprubartCorporate
Strategic partnership with Natera to incorporate Prospera test in Phase 3 trial
kidney transplantationsource ↗
▲Topline ReadoutTegoprubartClinical Data
All 12 Tegoprubart recipients off external insulin following islet implant
type 1 diabetessource ↗
▲End Of Phase 2 MeetingTegoprubartFDA Meeting
Successful End-of-Phase 2 meeting with FDA for tegoprubart in kidney transplantation
kidney transplantationsource ↗
▲First Patient DosedTegoprubartTrial
Treated first two patients in investigator-initiated study at Massachusetts General Hospital
kidney transplant tolerance inductionsource ↗
▲Partnership / LicenseTegoprubartCorporate
Strategic partnership with Natera for Prospera dd-cfDNA monitoring in Phase 3 trial
kidney transplantationsource ↗
◆Oral PresentationTegoprubartPresentation
Oral presentation of Phase 2 BESTOW trial data at ATC
kidney transplantationsource ↗
◆Quarterly UpdateTegoprubartCorporate
Conference call to discuss updated BESTOW data and long-term extension data
kidney transplantationsource ↗
◆Poster PresentationTegoprubartPresentation
Poster presentation of Phase 2 BESTOW extension trial long-term data at ATC
kidney transplantationsource ↗
◆Oral PresentationTegoprubartPresentation
Oral presentation of updated data from investigator-initiated islet transplant trial of tegoprubart at ADA 2026
Type 1 Diabetessource ↗
▲Oral PresentationTegoprubartPresentation
Updated results from investigator-initiated islet transplant trial presented at ADA 86th Scientific Sessions
type 1 diabetessource ↗
▲Oral PresentationTegoprubartPresentation
Long-term Phase 2 BESTOW data presented at ATC 2026
kidney transplantationsource ↗
▲Orphan Drug DesignationTegoprubartDesignation
FDA Orphan Drug designation granted for tegoprubart in liver transplantation
prevention of allograft rejection in liver transplantationsource ↗
▲Full ResultsTegoprubartClinical Data
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation
type 1 diabetes (islet transplantation)source ↗
▲Orphan Drug DesignationTegoprubartDesignation
Tegoprubart granted Orphan Drug designation by FDA for prevention of allograft rejection in liver transplantation
prevention of allograft rejection in liver transplantationsource ↗
◆Oral PresentationPresentation
Eledon Pharmaceuticals to participate in fireside chat at Leerink Partners 2026 Global Healthcare Conference
▲Oral PresentationTegoprubartPresentation
Updated results presented at ATTD conference
type 1 diabetessource ↗
▲Orphan Drug DesignationTegoprubartDesignation
FDA grants Orphan Drug designation to tegoprubart for prevention of allograft rejection in liver transplantation
prevention of allograft rejection in liver transplantationsource ↗
▲Full ResultsTegoprubartClinical Data
Updated results from investigator-led trial: 10 patients achieved 100% insulin independence
type 1 diabetes undergoing islet transplantationsource ↗
◆Oral PresentationPresentation
Eledon Pharmaceuticals to participate in Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat
◆Poster PresentationTegoprubartPresentation
Poster presentation of 24-month follow-up data from Phase 1b long-term extension of tegoprubart in kidney transplant recipients at ASTS Winter Symposium
kidney transplantationsource ↗
▲Oral PresentationTegoprubartPresentation
24-month follow-up data presented at American Society of Transplant Surgeons Winter Symposium
kidney transplantationsource ↗
◆Oral PresentationPresentation
Eledon Pharmaceuticals to participate in fireside chat at 37th Annual Piper Sandler Healthcare Conference
▲Topline ReadoutTegoprubartClinical Data
Preliminary topline data from first six patients in islet transplant trial
type 1 diabetessource ↗
▲Enrollment UpdateTegoprubartTrial
Trial extended to include total of 12 subjects
type 1 diabetessource ↗
▲Oral PresentationTegoprubartPresentation
Preliminary data from first six patients presented at Rachmiel Levine-Arthur Riggs Diabetes Research Symposium
type 1 diabetessource ↗
▼Equity OfferingCorporate
Completed underwritten public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Pricing of $50 million underwritten public offering of common stock and pre-funded warrants
◆Oral PresentationPresentation
Eledon Pharmaceuticals to present at Guggenheim Second Annual Healthcare Innovation Conference
▼Equity OfferingCorporate
Eledon announces proposed underwritten public offering of common stock and pre-funded warrants
▲Late-BreakerTegoprubartPresentation
Late-breaking oral presentation of Phase 2 BESTOW trial results at ASN Kidney Week 2025
prevention of organ rejection in kidney transplantationsource ↗
▲Full ResultsTegoprubartClinical Data
Phase 2 BESTOW trial results presented
prevention of organ rejection in kidney transplantationsource ↗
▼Primary Endpoint MissedTegoprubartClinical Data
Primary endpoint (change in eGFR at 12 months) did not reach statistical significance
prevention of rejection in kidney transplantationsource ↗
▲Full ResultsTegoprubartClinical Data
Phase 2 BESTOW trial data showed favorable efficacy, safety and tolerability
kidney transplantationsource ↗
◆Topline ReadoutTegoprubartClinical Data
Topline results from Phase 2 BESTOW trial
prevention of organ rejection in kidney transplant patientssource ↗
▲Oral PresentationTegoprubartPresentation
Presented Phase 2 BESTOW results at ASN Kidney Week 2025
kidney transplant rejectionsource ↗
◆Oral PresentationTegoprubartPresentation
Plenary session presentation on anti-CD154 pathway blockade at IXA Congress
xenotransplantationsource ↗
◆Enrollment MilestoneTegoprubartTrial
Enroll final three patients in islet cell transplantation study
Type 1 diabetes (islet cell transplantation)source ↗
◆Topline ReadoutTegoprubartClinical Data
Top-line results expected for BESTOW trial
prevention of organ rejection in kidney transplant patientssource ↗
Past FDA Catalysts and PDUFA Decisions
How ELDN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-01 | tegoprubart | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$20M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 68%
Micro Cap(rank 449 of 660)
Percentile Rank
Eledon Pharmaceuticals, Inc. faces pipeline headwinds (30/100), with $179M risk-adjusted pipeline value, led by Tegoprubart in Kidney Transplant Rejection (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tegoprubart Small moleculeNCT05983770 | Kidney Transplant Rejection | Phase 3 | COMPLETED | 879 | Sep 25, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ELDN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| tegoprubart Fast TrackOrphan | kidney function improvement | Phase 2 | 2026-09-22 | mean e GFR treatment: 71 mL/min/1.73 m²; mean e GFR control: 58 mL/min/1.73 m²; advantage: approximately 13 mL/min/1.73 m²Read More | Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation SocietyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McBride John S.Director | Option | 3,430 3,430 held | $0.00 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ELDN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.6 % | 24.80 M | 6.29 M |
ELDN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-05-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ELDN ranks across every disease it competes in
Competitive Position is a premium feature
See how ELDN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialELDN News
ELDNEledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Eledon Pharmaceuticals has announced an oral presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting. The presentation will focus on patient-reported outcomes from the Phase 2 BESTOW trial, which evaluates tegoprubart for preventing rejection in kidney transplants. The session is scheduled for October 23, 2026, in Denver, CO.
Read more →ELDN▲ +7.4%on this news
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Eledon presented updated results from the Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. Patients treated with tegoprubart demonstrated a significant improvement in kidney function, with a mean eGFR of 71 mL/min/1.73 m² compared to 58 mL/min/1.73 m² for those on tacrolimus. Importantly, there were no rejections in the tegoprubart group beyond six months.
Read more →ELDNEledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
Eledon Pharmaceuticals announced an oral presentation at the International Congress of The Transplantation Society. The presentation will discuss the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection. Dr. Andrew Adams will lead the session, which is scheduled for September 22, 2026, in Sydney, Australia.
Read more →ELDNEledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
Eledon Pharmaceuticals has submitted an IND for a study of tegoprubart in islet cell transplantation for type 1 diabetes. The company has also enrolled its first patients in various studies related to kidney transplantation and is on track to initiate a Phase 3 trial in late 2026. The progress reflects the expanding clinical evaluation of tegoprubart across multiple transplant settings.
Read more →ELDNEledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals reported positive advancements in its clinical programs, including a successful End-of-Phase 2 meeting with the FDA for tegoprubart, which is set to enter a Phase 3 kidney transplantation trial in late 2026. The company presented promising long-term data showing improved kidney function and patient outcomes compared to the standard treatment. Additionally, all patients in an islet cell transplantation study achieved insulin independence. However, the company reported a significant net loss and a decrease in cash reserves.
Read more →ELDN▼ -7.8%on this newsshared move
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Natera and Eledon have formed a strategic partnership to utilize the Prospera monitoring assay in Eledon's upcoming Phase 3 trial of tegoprubart for kidney transplantation. This collaboration aims to enhance donor-derived cell-free DNA monitoring. The trial is anticipated to begin in late 2026, marking a significant step in kidney transplant research.
Read more →ELDNEledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Pharmaceuticals presented long-term results from its Phase 2 BESTOW trial at the American Transplant Congress, highlighting the advantages of tegoprubart over tacrolimus in kidney transplantation. Tegoprubart-treated patients exhibited significantly higher kidney function and no acute rejection events after six months. Additionally, patient-reported outcomes showed improved quality of life metrics. The company plans to advance into Phase 3 development following these promising results.
Read more →ELDNEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
Eledon Pharmaceuticals announced positive outcomes from a trial of tegoprubart, showing all 12 participants with type 1 diabetes achieved insulin independence and had significantly improved HbA1c levels. The study also reported no severe hypoglycemic events post-transplantation. The results suggest a potential advance in islet transplantation approaches, reducing reliance on traditional immunosuppressants like tacrolimus. Eledon aims to work with the FDA for guidance on a pathway to market for tegoprubart in this context.
Read more →ELDNEledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
Eledon Pharmaceuticals announced that updated results from an investigator-initiated trial of tegoprubart will be presented at the 2026 American Diabetes Association Scientific Sessions. The presentation, led by Dr. Piotr Witkowski, will focus on the use of anti-CD40L to enhance graft survival in islet allotransplantation. This highlights Eledon's efforts in developing immune-modulating therapies for type 1 diabetes. The conference takes place from June 5-9 in New Orleans, Louisiana.
Read more →ELDN▲ +7.3%on this news
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Eledon Pharmaceuticals announced that it will present new long-term clinical data from its tegoprubart program at the upcoming American Transplant Congress from June 20-24, 2026. This will include updated findings from the Phase 2 BESTOW trial and an extension study focused on preventing kidney transplant rejection. The presentations will feature expert input from Andrew Adams, M.D., Ph.D., highlighting the significance of tegoprubart in transplantation therapies. Following the presentations, a conference call will provide further insights into the data shared at the Congress.
Read more →ELDNEledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals reported its Q1 2026 financial results, showcasing significant progress in its tegoprubart program. Notably, 100% insulin independence was achieved in 10 patients with type 1 diabetes after islet transplantation, and the FDA granted Orphan Drug designation to tegoprubart for liver transplantation. Despite a higher net loss compared to the previous year, the company expects several regulatory engagements and new clinical trials in the coming year to advance its innovative therapies.
Read more →ELDNEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
Eledon Pharmaceuticals reported its fourth quarter and full year 2025 results, highlighting progress with tegoprubart, an anti-CD40L antibody. The drug has shown a favorable safety profile in clinical trials and received Orphan Drug designation for liver transplantation. The company anticipates multiple milestones, including advancing to Phase 3 trials in kidney transplantation and initiating new trials in islet and liver transplantation.
Read more →ELDNEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
Eledon Pharmaceuticals announced promising results from a trial of tegoprubart in Type 1 Diabetes patients undergoing islet transplantation. All 10 patients studied achieved insulin independence, with stable graft functions observed. Important safety outcomes indicated no graft rejection and minimal adverse effects associated with traditional immunosuppressants. The trial was conducted at UChicago Medicine and reflects potential advancement in diabetes treatment options.
Read more →ELDNEledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
Eledon Pharmaceuticals announced that the FDA granted Orphan Drug designation to tegoprubart for preventing allograft rejection in liver transplantation. This designation is intended to encourage therapies for rare diseases with high unmet medical needs. Previous studies have shown that tegoprubart could improve graft survival while minimizing side effects commonly associated with traditional immunosuppressants. The company is optimistic about the potential of tegoprubart in this area and plans to initiate a clinical trial soon. Despite the positive developments, challenges related to clinical trial execution remain.
Read more →ELDNEledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
Eledon Pharmaceuticals will participate in the Leerink Partners 2026 Global Healthcare Conference, featuring a fireside chat with CEO David-Alexandre C. Gros and President Steven Perrin. The event is scheduled for March 11, 2026. Eledon focuses on developing immune-modulating therapies, particularly its lead product, tegoprubart, targeting CD40L for various serious medical conditions.
Read more →ELDN▲ +11.2%on this newsshared move
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Eledon Pharmaceuticals will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with a fireside chat featuring Steven Perrin, Ph.D., on February 12, 2026. The company is known for its development of immune-modulating therapies, particularly its lead product, tegoprubart, which targets CD40 Ligand. This participation highlights Eledon's commitment to advancing its clinical stage biotechnology initiatives.
Read more →ELDNEledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
Eledon Pharmaceuticals presented long-term Phase 1b data for tegoprubart at the American Society of Transplant Surgeons Winter Symposium. The study involved eight kidney transplant patients, showing no acute rejection or graft loss. Notably, the mean estimated glomerular filtration rate (eGFR) increased significantly over 24 months, indicating positive outcomes for the treatment.
Read more →About Eledon Pharmaceuticals, Inc.
Headquarters19800 MACARTHUR BLVD., IRVINE, CA, 92612
BIOPHARMAWATCH ELITE PLUS
Trade the next ELDN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime